Published in Biol Blood Marrow Transplant on July 27, 2012
DiseaseConnect: a comprehensive web server for mechanism-based disease-disease connections. Nucleic Acids Res (2014) 0.99
Allogeneic hematopoietic cell transplantation for myelofibrosis using fludarabine-, intravenous busulfan- and low-dose TBI-based conditioning. Bone Marrow Transplant (2014) 0.79
Pharmacokinetically-targeted BU and fludarabine as conditioning before allogeneic hematopoietic cell transplantation for adults with ALL in first remission. Bone Marrow Transplant (2013) 0.77
Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia. J Hematol Oncol (2016) 0.75
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood (2012) 5.11
Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant (2009) 5.10
The pace of shifting climate in marine and terrestrial ecosystems. Science (2011) 4.97
Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst (2013) 3.63
Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care (2006) 3.47
Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol (2010) 3.46
Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. Nat Genet (2011) 3.41
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med (2014) 2.99
Migration of bone marrow and cord blood mesenchymal stem cells in vitro is regulated by stromal-derived factor-1-CXCR4 and hepatocyte growth factor-c-met axes and involves matrix metalloproteinases. Stem Cells (2006) 2.85
The commission on social determinants of health: tackling the social roots of health inequities. PLoS Med (2006) 2.84
Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood (2004) 2.83
Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet Neurol (2009) 2.48
A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood (2012) 2.11
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood (2014) 2.01
Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors. Blood (2011) 2.01
An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol (2012) 1.94
Agranulocytosis after consumption of cocaine adulterated with levamisole. Ann Intern Med (2009) 1.91
Possible links between behavioral and physiological indices of tiredness, fatigue, and exhaustion in advanced cancer. Support Care Cancer (2007) 1.68
Suppression of experimental autoimmune encephalomyelitis by selective blockade of encephalitogenic T-cell infiltration of the central nervous system. Nat Med (2003) 1.62
Induction of cytotoxic T-lymphocyte responses to enhanced green and yellow fluorescent proteins after myeloablative conditioning. Blood (2003) 1.61
Fludarabine and 2-Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related hematopoietic cell transplantation: a phase III randomized trial. Biol Blood Marrow Transplant (2013) 1.51
An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk (2012) 1.48
Immune reconstitution after hematopoietic cell transplantation. Curr Opin Hematol (2012) 1.48
High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen. Biol Blood Marrow Transplant (2008) 1.46
Changing volumes, risk profiles, and outcomes of coronary artery bypass grafting and percutaneous coronary interventions. Ann Thorac Surg (2009) 1.45
Visualization of hypoxia in microscopic tumors by immunofluorescent microscopy. Cancer Res (2007) 1.45
Reconstitution of the immune system after hematopoietic stem cell transplantation in humans. Semin Immunopathol (2008) 1.42
Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol (2003) 1.41
Increasing incidence rates, distribution and histological characteristics of primary gastrointestinal non-Hodgkin lymphoma in a North American population. Can J Gastroenterol (2012) 1.35
An affective circumplex model of neural systems subserving valence, arousal, and cognitive overlay during the appraisal of emotional faces. Neuropsychologia (2008) 1.32
Knowledge and attitudes regarding care of leg ulcers. Survey of family physicians. Can Fam Physician (2003) 1.31
Conjugating recombinant proteins to Pseudomonas aeruginosa ExoProtein A: a strategy for enhancing immunogenicity of malaria vaccine candidates. Vaccine (2007) 1.28
Rates of obstetric intervention among low-risk women giving birth in private and public hospitals in NSW: a population-based descriptive study. BMJ Open (2012) 1.27
Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis. Biol Blood Marrow Transplant (2007) 1.26
High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. Blood (2002) 1.26
High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood (2003) 1.25
Immunologic recovery after hematopoietic cell transplantation with nonmyeloablative conditioning. Exp Hematol (2003) 1.25
Reliability, construct validity, and responsiveness of the neck disability index, patient-specific functional scale, and numeric pain rating scale in patients with cervical radiculopathy. Am J Phys Med Rehabil (2010) 1.23
Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. Blood (2010) 1.23
Compensation for nucleotide bias in a genome by representation as a discrete channel with noise. Bioinformatics (2002) 1.21
Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 CGY total-body irradiation, and thymoglobulin. Biol Blood Marrow Transplant (2007) 1.20
Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases. Biol Blood Marrow Transplant (2003) 1.18
Production and characterization of clinical grade Escherichia coli derived Plasmodium falciparum 42 kDa merozoite surface protein 1 (MSP1(42)) in the absence of an affinity tag. Protein Expr Purif (2006) 1.14
Iron accumulation in deep cortical layers accounts for MRI signal abnormalities in ALS: correlating 7 tesla MRI and pathology. PLoS One (2012) 1.13
18F-fluromisonidazole PET imaging as a biomarker for the response to 5,6-dimethylxanthenone-4-acetic acid in colorectal xenograft tumors. J Nucl Med (2011) 1.11
Winter planning. Seasonal cycles. Health Serv J (2002) 1.11
Ca2+ influx-independent synaptic potentiation mediated by mitochondrial Na(+)-Ca2+ exchanger and protein kinase C. J Cell Biol (2003) 1.11
Effect of bearing size on the long-term wear, wear debris, and ion levels of large diameter metal-on-metal hip replacements-An in vitro study. J Biomed Mater Res B Appl Biomater (2008) 1.09
Predominance of interleukin-22 over interleukin-17 at the site of disease in human tuberculosis. Tuberculosis (Edinb) (2011) 1.08
Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Depress Anxiety (2008) 1.07
An international comparison of current strategies to prevent herpesvirus and fungal infections in hematopoietic cell transplant recipients. Biol Blood Marrow Transplant (2010) 1.06
The ghost condition: imitation versus emulation in young children's observational learning. Dev Psychol (2004) 1.06
The addition of 400 cGY total body irradiation to a regimen incorporating once-daily intravenous busulfan, fludarabine, and antithymocyte globulin reduces relapse without affecting nonrelapse mortality in acute myelogenous leukemia. Biol Blood Marrow Transplant (2009) 1.04
Survivor treatment selection bias and outcomes research: a case study of surgery in infective endocarditis. Circ Cardiovasc Qual Outcomes (2009) 1.04
Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. Haematologica (2003) 1.03
Fifth complement cascade protein (C5) cleavage fragments disrupt the SDF-1/CXCR4 axis: further evidence that innate immunity orchestrates the mobilization of hematopoietic stem/progenitor cells. Exp Hematol (2010) 1.02
Hematopoietic stem cell transplantation for multiple sclerosis: collaboration of the CIBMTR and EBMT to facilitate international clinical studies. Biol Blood Marrow Transplant (2010) 1.02
Tumour on the tricuspid valve: metastatic osteosarcoma and the heart. Can J Cardiol (2005) 1.02
Immune reconstitution after anti-thymocyte globulin-conditioned hematopoietic cell transplantation. Cytotherapy (2012) 1.01
Comparison of outcomes after transplantation of G-CSF-stimulated bone marrow grafts versus bone marrow or peripheral blood grafts from HLA-matched sibling donors for patients with severe aplastic anemia. Biol Blood Marrow Transplant (2010) 1.01
The HGF/c-Met axis synergizes with G-CSF in the mobilization of hematopoietic stem/progenitor cells. Stem Cells Dev (2010) 1.01
Hypoxic regulation of cytoglobin and neuroglobin expression in human normal and tumor tissues. Cancer Cell Int (2010) 1.01
The ins and outs of hematopoietic stem cells: studies to improve transplantation outcomes. Stem Cell Rev (2011) 1.01
Valproic acid increases CXCR4 expression in hematopoietic stem/progenitor cells by chromatin remodeling. Stem Cells Dev (2009) 0.99
Changing epidemiology and risk factors for gastrointestinal non-Hodgkin's lymphoma in a North American population: population-based study. Am J Gastroenterol (2008) 0.98
Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion. Blood (2011) 0.97
Low-dose total body irradiation and fludarabine conditioning for HLA class I-mismatched donor stem cell transplantation and immunologic recovery in patients with hematologic malignancies: a multicenter trial. Biol Blood Marrow Transplant (2009) 0.97
Unrelated donor status and high donor age independently affect immunologic recovery after nonmyeloablative conditioning. Biol Blood Marrow Transplant (2006) 0.97
HIV-1 infection alters CD4+ memory T-cell phenotype at the site of disease in extrapulmonary tuberculosis. Eur J Immunol (2012) 0.97
Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial. Int Clin Psychopharmacol (2007) 0.96
Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancer. J Natl Cancer Inst (2011) 0.96
Bacteraemia due to dental flossing. J Clin Periodontol (2009) 0.96
Immune reconstitution following hematopoietic stem-cell transplantation. Best Pract Res Clin Haematol (2007) 0.96
Decreased infections in recipients of unrelated donor hematopoietic cell transplantation from donors with an activating KIR genotype. Biol Blood Marrow Transplant (2010) 0.96
Reovirus as a viable therapeutic option for the treatment of multiple myeloma. Clin Cancer Res (2012) 0.95
Detecting changes in tumor hypoxia with carbonic anhydrase IX and pimonidazole. Cancer Biol Ther (2007) 0.95
Interaural level differences and sound source localization for bilateral cochlear implant patients. Ear Hear (2014) 0.95
Cytomegalovirus viral load and virus-specific immune reconstitution after peripheral blood stem cell versus bone marrow transplantation. Biol Blood Marrow Transplant (2011) 0.95
Is allergic disease curable or transferable with allogeneic hematopoietic cell transplantation? Blood (2008) 0.94
Identification and characterization of antifungal compounds using a Saccharomyces cerevisiae reporter bioassay. PLoS One (2012) 0.94
Transplantation for autoimmune diseases in north and South America: a report of the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant (2012) 0.94
Continued disease activity in a patient with multiple sclerosis after allogeneic hematopoietic cell transplantation. Arch Neurol (2009) 0.93
Synthesis and SAR studies of very potent imidazopyridine antiprotozoal agents. Bioorg Med Chem Lett (2006) 0.93
Polyneuropathy with Impaired Glucose Tolerance: Implications for Diagnosis and Therapy. Curr Treat Options Neurol (2005) 0.93
A quantitative overview of radiosensitivity of human tumor cells across histological type and TP53 status. Int J Radiat Biol (2008) 0.93
Targeting hypoxia and angiogenesis through HIF-1alpha inhibition. Cancer Biol Ther (2005) 0.92
MT1-MMP association with membrane lipid rafts facilitates G-CSF--induced hematopoietic stem/progenitor cell mobilization. Exp Hematol (2010) 0.92
Cutaneous angiosarcoma of the scalp: a case report of sustained complete response following liposomal Doxorubicin and radiation therapy. Sarcoma (2005) 0.91